Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
112.31
-6.99 (-5.86%)
Real-time:   2:04PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 112.09 - 116.45
52 week 94.15 - 128.96
Open 116.07
Vol / Avg. 7.79M/3.88M
Mkt cap 85.02B
P/E 18.23
Div/yield 0.61/2.17
EPS 6.16
Shares 757.00M
Beta 0.51
Inst. own 82%
May 15, 2014
Amgen 2014 Annual Shareholder Meeting - 2:00PM EDT - Add to calendar
Apr 22, 2014
Q1 2014 Amgen Earnings Conference Call - Webcast
Apr 22, 2014
Q1 2014 Amgen Earnings Release
Mar 30, 2014
Amgen Investor Meeting, ACC Scientific Session 2014 - Webcast
Mar 29, 2014
Amgen at American College of Cardiology (ACC) 2014: 63rd Annual Scientific Session & Expo
Mar 10, 2014
Amgen at EBD BIO-Europe Spring
Mar 4, 2014
Amgen at Credit Suisse Healthcare Conference
Mar 3, 2014
Amgen at Cowen Health Care Conference
Feb 26, 2014
Amgen at RBC Capital Markets Healthcare Conference - Webcast
Feb 25, 2014
Amgen at Citi Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 23.73% 27.21%
Operating margin 30.17% 31.41%
EBITD margin - 39.90%
Return on average assets 6.47% 8.44%
Return on average equity 19.20% 24.69%
Employees 20,000 -
CDP Score - 76 B

Address

One Amgen Center Drive
THOUSAND OAKS, CA 91320-1799
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In September 2013, Swedish Orphan Biovitrum AB (publ) (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen Inc for all therapeutic indications.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Michael A. Kelly Acting Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 63
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 51
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 59
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 57
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 52
Bio & Compensation  - Reuters
David J. Scott Senior Vice President, General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Stuart A. Tross Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Vance D. Coffman Lead Independent Director
Age: 70
Bio & Compensation  - Reuters